

SAGE Therapeutics Inc

COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 06-Jun-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



PLEASE NOTE: the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 8

Product Portfolio Summary..... 13

Product Portfolio Drugs..... 16

[Return to Table of Contents](#)

SAGE Therapeutics Inc

COMPANY OVERVIEW

| | |
|---------------------------------------|--|
| Company Name | SAGE Therapeutics Inc |
| Parent Company Name | SAGE Therapeutics Inc |
| Website | http://www.sagerx.com/ |
| Country | US |
| Number of Drugs in Active Development | 6 |
| Number of Inactive Drugs | 4 |
| Number of Patents as Owner | 16 |
| Number of Patents as Third Party | 0 |
| Number of Deals | 4 |
| Key Indications | Status epilepticus, Central nervous system disease, Psychiatric disorder, Epilepsy, Anesthesia, Rett syndrome, Essential tremor, Mood disorder, Neurological disease, Postnatal depression |
| Key Target-based Actions | GABA A receptor modulator, NMDA receptor modulator, GABA A receptor alpha-1 subunit modulator, GABA A receptor alpha-4 subunit modulator, GABA A receptor delta subunit modulator, GABA A receptor beta-2 subunit inhibitor, GABA A receptor beta-3 subunit inhibitor, GABA A receptor gamma-2 subunit inhibitor, GABA A receptor agonist, GABA A receptor alpha-1 subunit stimulator, GABA A receptor beta-2 subunit modulator, GABA A receptor beta-2 subunit stimulator, GABA A receptor beta-3 subunit modulator, GABA A receptor gamma-2 subunit modulator, GABA A receptor gamma-2 subunit stimulator, GABA B receptor agonist, GABA receptor antagonist, GABA receptor modulator, NMDA receptor agonist |
| Key Technologies | Small molecule therapeutic, Intravenous formulation, Oral formulation, Steroid, Infusion, Analytical method, Pharmaceutical carrier |

COMPANY PROFILE

SUMMARY

SAGE Therapeutics is a pharmaceutical company, focused on developing medicines for central nervous system disorders.

FINANCIAL

In April 2015, the company priced an underwritten public offering of 2,285,714 shares of its common stock at a public offering price of \$52.50 per share. The company granted the underwriters a 30-day option to purchase up to an additional 342,857 shares of common stock. At that time, the offering was expected to close on or about April 20, 2015. Later that month, the offering was closed with 2,628,571 shares sold including the full exercise of the additional shares offered. At that time, the company raised gross proceeds of approximately \$138 million.

In April 2015, the company proposed an underwritten public offering of \$100 million of shares of its common stock. The company granted the underwriters a 30-day option to purchase up to an additional \$15 million of shares of common stock.

In December 2014, the company was added to the NASDAQ Biotechnology Index (NBI) which would become effective upon market open on December 22, 2014.

In July 2014, the company announced the pricing of its initial public offering of 5 million shares of common stock at a price of \$18 per share. The underwriters were also granted a 30-day option to buy up to an additional 0.75 shares at the same offering price to cover over-allotments, if any. The company's shares were expected to begin trading on the NASDAQ Global market on July 18, 2014, under the ticker symbol 'SAGE'. Later that month, the underwriters exercised their full option to purchase additional shares of the IPO. At that time, the company raised a capital of \$103.5 million from a total of 5.75 million shares sold and the offering was closed.

[Return to Table of Contents](#)



In March 2014, the company raised \$38 million from an oversubscribed series C financing.

In October 2013, the company raised \$20 million from a series B financing.

In October 2011, SAGE secured \$35 million in series A financing. By September 2013, the company raised \$37.8 million totally from the completion of series A financing.

COMPANY FINANCIALS

SHARE INFORMATION

| | |
|--------------------------------------|-------------------|
| Close Price (USD) | 80.82 |
| Change (USD) | 2.21 (2.81%) |
| Previous Close Price (USD) | 78.61 |
| Volume | 172,786 |
| 52-Week High (USD) | 81.20 |
| 52-Week Low (USD) | 24.25 |
| Date | 05-Jun-2015 |
| Exchange | NASDAQ(COMPOSITE) |
| Current Number of Shares Outstanding | 28,366,696 |
| Current Market Capitalization | 2,123,814,530 |
| EPS (Date Reported) | -1.67352 |

[Return to Table of Contents](#)

STOCK PERFORMANCE



MAJOR SHAREHOLDERS

| Shareholder | Type | Country | Shares held | % of shares held | Change in holding | % changes in shares held | Date |
|---|---------------------|---------------|-------------|------------------|-------------------|--------------------------|-------------|
| Fidelity Select Biotechnology Portfolio | Mutual Fund | United States | 1,270,883 | 4.48 | 27,200 | 0.02 | 30-Apr-2015 |
| Paul (Steven M) | Individual Investor | United States | 743,650 | 2.62 | -60,000 | -0.07 | 01-Jun-2015 |
| Fidelity Growth Company Fund | Mutual Fund | United States | 938,366 | 3.31 | 71,477 | 0.08 | 30-Apr-2015 |
| iShares NASDAQ Biotechnology ETF | Mutual Fund | United States | 361,632 | 1.27 | 41,745 | 0.13 | 31-May-2015 |
| BlackRock Health Sciences Opportunities Portfolio | Mutual Fund | United States | 328,187 | 1.16 | 58,800 | 0.22 | 30-Apr-2015 |
| Robichaud (Albert J) | Individual Investor | United States | 210,222 | 0.74 | -16,000 | -0.07 | 01-Jun-2015 |
| Vanguard Small-Cap Index Fund | Mutual Fund | United States | 259,655 | 0.92 | 47,559 | 0.22 | 30-Apr-2015 |
| Vanguard Total Stock Market Index Fund | Mutual Fund | United States | 248,850 | 0.88 | 38,300 | 0.18 | 30-Apr-2015 |
| Fidelity Series Growth Company Fund | Mutual Fund | United States | 239,410 | 0.84 | 20,200 | 0.09 | 30-Apr-2015 |


[Return to Table of Contents](#)



| | | | | | | | |
|---|---------------------|---------------|---------|------|---------|-------|-------------|
| Fidelity Advisor Biotechnology Fund | Mutual Fund | United States | 236,272 | 0.83 | 6,111 | 0.03 | 30-Apr-2015 |
| Vanguard Small-Cap Value Index Fund | Mutual Fund | United States | 148,867 | 0.52 | 30,805 | 0.26 | 30-Apr-2015 |
| JPMorgan Small Cap Growth Fund | Mutual Fund | United States | 139,042 | 0.49 | 0 | 0 | 30-Apr-2015 |
| Fidelity Contrafund | Mutual Fund | United States | 136,257 | 0.48 | 136,257 | 1 | 30-Apr-2015 |
| iShares Russell 2000 ETF | Mutual Fund | United States | 96,123 | 0.34 | -4,252 | -0.04 | 31-May-2015 |
| Iguchi (Kimi) | Individual Investor | United States | 98,063 | 0.35 | 0 | 0 | 02-Apr-2015 |
| Vanguard Extended Market Index Fund | Mutual Fund | United States | 76,943 | 0.27 | 27,531 | 0.56 | 30-Apr-2015 |
| iShares Russell 2000 Growth ETF | Mutual Fund | United States | 43,353 | 0.15 | 3,127 | 0.08 | 31-May-2015 |
| Kanes Stephen | Individual Investor | United States | 46,948 | 0.17 | -5,400 | -0.1 | 02-Apr-2015 |
| Principal SmallCap Growth Fund I | Mutual Fund | United States | 45,868 | 0.16 | 0 | 0 | 30-Apr-2015 |
| SEI Institutional Investments - Small/Mid Cap Equity Fund | Mutual Fund | United States | 44,650 | 0.16 | -9,362 | -0.17 | 30-Apr-2015 |

[Return to Table of Contents](#)





| | 2012 | 2013 | 2014 | | |
|--------------------------|--------|---------|---------|--|--|
| Sales (USD M) | 0 | 0 | 0 | | |
| Operating Income (USD M) | -9.631 | -18.279 | -33.81 | | |
| Net Income (USD M) | -9.636 | -18.288 | -36.105 | | |

[Return to Table of Contents](#)

Quarterly earnings update

| Period | Sales (USD M) | Operating Income (USD M) | Net Income (USD M) |
|---------|---------------|--------------------------|--------------------|
| 2015 Q1 | 0 | -16.897 | -16.871 |
| 2014 Q4 | 0 | -12.361 | -12.361 |
| 2014 Q3 | 0 | -9.47 | -9.859 |
| 2014 Q2 | 0 | -6.188 | -7.769 |
| 2014 Q1 | 0 | -5.79 | -6.116 |
| 2013 Q3 | 0 | -4.519 | -4.519 |
| 2013 Q2 | 0 | -4.655 | -4.655 |
| 2013 Q1 | 0 | -3.389 | -3.389 |

BALANCE SHEET

Assets (USD M)

| | 2012 | 2013 | 2014 | | |
|-------------------------------------|-------|-------|---------|--|--|
| Cash & Short Term Investments | 2.802 | 8.066 | 127.766 | | |
| Inventories - Total | 0 | 0 | 0 | | |
| Current Assets - Total | 2.826 | 8.407 | 128.822 | | |
| Property, Plant And Equipment - Net | 0.13 | 0.086 | 0.163 | | |
| Other Assets - Total | 0 | 0 | 0 | | |
| Total Assets | 2.995 | 8.532 | 129.024 | | |

Liabilities (USD M)

| | 2012 | 2013 | 2014 | | |
|---|-------|-------|--------|--|--|
| Accounts Payable | 1.314 | 1.988 | 2.429 | | |
| Short Term Debt & Current Portion Of Long Term Debt | 0 | 0 | 0 | | |
| Current Liabilities - Total | 1.419 | 2.315 | 7.757 | | |
| Long Term Debt | 0 | 0 | 0 | | |
| Deferred Taxes | | | -0.641 | | |
| Other Liabilities | 0 | 0.044 | 0.023 | | |
| Total Liabilities | 1.419 | 2.359 | 7.139 | | |

[Return to Table of Contents](#)



Stockholders Equity (USD M)

| | 2012 | 2013 | 2014 | | |
|--|-------|--------|---------|--|--|
| Minority Interest | 0 | 0 | 0 | | |
| Preferred Stock | 14.97 | 37.709 | 0 | | |
| Common Stock | 0 | 0 | 0.003 | | |
| Treasury Stock | 0 | | | | |
| Total Liabilities & Shareholders' Equity | 2.995 | 8.532 | 129.024 | | |

FORECASTS

EPS Forecast

| Year ending | Current Forecast | 1 month ago | 3 months ago |
|-------------|------------------|-------------|--------------|
| 31-Dec-2015 | -2.46 | -2.36 | -2.09 |
| 31-Dec-2016 | -2.99 | -2.8 | -2.71 |
| 31-Dec-2017 | -2.88 | -2.53 | -2.88 |

Other Forecasts

| Year ending | DPS | CPS | Pretax | Sales |
|-------------|-----|-------|--------|-------|
| 31-Dec-2015 | 0 | -2.64 | -72.08 | 0 |
| 31-Dec-2016 | 0 | | -87.11 | 0 |
| 31-Dec-2017 | | | -92.68 | 20.78 |

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

| Indication | Active | Inactive | Total |
|----------------------|--------|----------|-------|
| Neurological disease | 6 | 4 | 10 |
| Psychiatric disorder | 4 | 0 | 4 |
| Injury | 0 | 1 | 1 |

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

| Development Status | Number of Drugs |
|-------------------------|-----------------|
| Phase 3 Clinical | 1 |
| Discovery | 5 |
| No Development Reported | 4 |

DEALS

| Deal Type | Principal | | Partner | | Total |
|--|-----------|----------|---------|----------|-------|
| | Active | Inactive | Active | Inactive | |
| Technology - Other Proprietary | 0 | 0 | 1 | 0 | 1 |
| Drug - Funding | 1 | 0 | 0 | 0 | 1 |
| Drug - Early Research/Development | 0 | 0 | 1 | 0 | 1 |
| Drug - Development/Commercialization License | 0 | 0 | 1 | 0 | 1 |

CLINICAL TRIALS

Trials by Condition Studied

| Condition Studied | Ongoing | All |
|-------------------|---------|-----|
|-------------------|---------|-----|

[Return to Table of Contents](#)

Trials by Condition Studied

| Condition Studied | Ongoing | All |
|----------------------|---------|-----|
| Neurological disease | 1 | 8 |
| Psychiatric disorder | 0 | 1 |

Trials by Phase

| Phase | Ongoing | All |
|---------------------|---------|-----|
| Phase 3 | 0 | 1 |
| Phase 2 | 0 | 4 |
| Phase 1 | 1 | 1 |
| Phase not specified | 0 | 3 |

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

| Indication | As Owner | As Third Party | Total |
|--------------------------------|----------|----------------|-------|
| Cardiovascular disease | 7 | 0 | 7 |
| Degeneration | 1 | 0 | 1 |
| Psychiatric disorder | 12 | 0 | 12 |
| Genetic disorder | 8 | 0 | 8 |
| Neurological disease | 17 | 0 | 17 |
| Injury | 8 | 0 | 8 |
| Toxicity and intoxication | 10 | 0 | 10 |
| Otorhinolaryngological disease | 6 | 0 | 6 |

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

SAGE-547

| | |
|-----------------------------|---|
| Drug Name | SAGE-547 |
| Key Synonyms | |
| Originator Company | SAGE Therapeutics Inc |
| Active Companies | SAGE Therapeutics Inc |
| Inactive Companies | |
| Highest Status | Phase 3 Clinical |
| Active Indications | Status epilepticus, Postnatal depression, Essential tremor |
| Target-based Actions | GABA A receptor modulator |
| Other Actions | Anticonvulsant agent, Neuroprotectant |
| Technologies | Intravenous formulation, Infusion, Small molecule therapeutic |
| Last Change Date | 15-May-2015 |

allosteric NMDA receptor modulators (CNS disorders), SAGE

| | |
|-----------------------------|---|
| Drug Name | allosteric NMDA receptor modulators (CNS disorders), SAGE |
| Key Synonyms | |
| Originator Company | SAGE Therapeutics Inc |
| Active Companies | SAGE Therapeutics Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Psychiatric disorder, Central nervous system disease |
| Target-based Actions | NMDA receptor modulator |
| Other Actions | Neuroprotectant |
| Technologies | Small molecule therapeutic |
| Last Change Date | 24-Feb-2015 |

[Return to Table of Contents](#)

allosteric modulators (Captisol, CNS disorders), Ligand/ SAGE

| | |
|-----------------------------|---|
| Drug Name | allosteric modulators (Captisol, CNS disorders), Ligand/ SAGE |
| Key Synonyms | |
| Originator Company | Ligand Pharmaceuticals Inc |
| Active Companies | SAGE Therapeutics Inc, Ligand Pharmaceuticals Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Central nervous system disease |
| Target-based Actions | |
| Other Actions | CNS modulator, Unspecified drug target |
| Technologies | Small molecule therapeutic |
| Last Change Date | 25-Mar-2015 |

SAGE-689

| | |
|-----------------------------|---|
| Drug Name | SAGE-689 |
| Key Synonyms | |
| Originator Company | SAGE Therapeutics Inc |
| Active Companies | SAGE Therapeutics Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Status epilepticus, Anesthesia |
| Target-based Actions | |
| Other Actions | Anesthetic, Unspecified drug target, Anticonvulsant agent |
| Technologies | Intravenous formulation, Small molecule therapeutic |
| Last Change Date | 02-Mar-2015 |

[Return to Table of Contents](#)

GABA A allosteric modulators (neuropsychiatric diseases), SAGE Therapeutics / Washington University in St. Louis

| | |
|-----------------------------|--|
| Drug Name | GABA A allosteric modulators (neuropsychiatric diseases), SAGE Therapeutics / Washington University in St. Louis |
| Key Synonyms | |
| Originator Company | SAGE Therapeutics Inc |
| Active Companies | Washington University in St Louis, SAGE Therapeutics Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Neurological disease, Psychiatric disorder |
| Target-based Actions | GABA A receptor modulator |
| Other Actions | Neuroprotectant |
| Technologies | Small molecule therapeutic |
| Last Change Date | 26-Nov-2014 |

SAGE-217

| | |
|-----------------------------|---|
| Drug Name | SAGE-217 |
| Key Synonyms | |
| Originator Company | SAGE Therapeutics Inc |
| Active Companies | SAGE Therapeutics Inc |
| Inactive Companies | |
| Highest Status | Discovery |
| Active Indications | Rett syndrome, Epilepsy |
| Target-based Actions | GABA A receptor modulator |
| Other Actions | Neuroprotectant, Anticonvulsant agent |
| Technologies | Oral formulation, Small molecule therapeutic, Steroid |
| Last Change Date | 15-May-2015 |

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

